Évaluation médico-économique, comparative en vie réelle de la morbi-mortalité post-traitement par résection endoscopique par DISsection sous muqueuse vers COlectomie dans le traitement des grandes lésions coliques superficielles en France (DISCO)

First published: 05/02/2026

Last updated: 05/02/2026

Study Planned

Administrative details

EU PAS number

EUPAS1000000919

Study ID

1000000919

DARWIN EU® study

No

Study countries

France

Study description

Colorectal cancer is the third most common cancer in France and the second most common in terms of mortality. As a possible alternative to surgery (colectomy), large polyps (>2 cm) can benefit from minimally invasive endoscopic resection techniques such as submucosal dissection.

The main objective is to evaluate the real-life efficiency at 2 years, based on a cost/effectiveness analysis expressed in cost per life year gained, of endoscopic resection using submucosal dissection versus laparoscopic colectomy in the treatment of large superficial colonic lesions from the perspective of the French healthcare system.

The DISCO study is based on SNDS data linked to data from the FECCo registry, which includes all individuals who have undergone Endoscopic Submucosal Dissection. The study period includes patients from 2019 with follow-up until 2024. The DISCO study is designed under the Target Trial Emulation framework.

If submucosal dissection is shown to be more effective than colectomy, offering monobloc endoscopic resection by this approach for benign lesions or superficial colorectal cancers would avoid major surgery, thereby limiting scarring and speeding up recovery. This would thus improve patients' quality of life and reduce the costs associated with hospitalization, time off work, and the management of complications.

Study status

Planned

Research institutions and networks

Institutions

Bordeaux University Hospital (CHU de Bordeaux)

France

First published: 01/02/2024

Last updated: 01/02/2024

Institution | Hospital/Clinic/Other health care facility

Bordeaux PharmacoEpi, University of Bordeaux

France

First published: 07/02/2023

Last updated: 08/12/2025

Institution | Educational Institution | Hospital/Clinic/Other health care facility | Not-for-profit | ENCePP partner

Contact details

Study institution contact

Nadège ANSOULT nadege.ansoult@chu-bordeaux.fr

Study contact

nadege.ansoult@chu-bordeaux.fr

Primary lead investigator

Arthur BERGER 0000-0003-0387-4734

Primary lead investigator

ORCID number:

0000-0003-0387-4734

Study timelines

Date when funding contract was signed
Planned: 30/06/2026

Study start date
Planned: 01/01/2027

Data analysis start date
Planned: 01/01/2027

Date of final study report
Planned: 31/03/2028

Sources of funding

- Other public funding (e.g. hospital or university)

More details on funding

PRME

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Medical procedure

Study type:

Non-interventional study

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Système National des Données de Santé (French national health system main database)

Data source(s), other

Registre FECCo

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Not applicable